Skip to main content
Medigene AG logo

Medigene AG — Investor Relations & Filings

Ticker · MDG1 ISIN · DE000A40ESG2 LEI · 391200I33JD2DKZGDX06 F Professional, scientific and technical activities
Open in API
Filings indexed 114 across all filing types
Latest filing 2013-10-30 Annual Report
Country DE Germany
Listing F MDG1

About Medigene AG

https://medigene.com/

Medigene AG is a biotechnology company that develops T-cell receptor (TCR)-guided immunotherapies for the treatment of cancer. The company utilizes its proprietary End-to-End platform to discover and develop optimized 3S (sensitive, specific, safe) TCRs. These TCRs are designed for application across various therapeutic modalities, including TCR-T cell therapies, TCR-T cell engagers, and TCR-natural killer cell therapies, targeting different forms of cancer. A key clinical program is MDG1015, a third-generation TCR-T therapy targeting the NY-ESO-1/LAGE-1a antigen, which is enhanced with a PD1-41BB costimulatory switch protein. As of August 2025, the company is undergoing insolvency proceedings.

Recent filings

Filing Released Lang Actions
Datum:30.10.2013
Annual Report Classification · 100% confidence The document is a comprehensive annual financial report for Medigene AG for the fiscal year 2012. It includes the balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), notes to the financial statements (Anhang), and the auditor's report (Bestätigungsvermerk). This constitutes a full annual financial report, which falls under the 10-K category in the provided schema. FY 2012
2013-10-30 German
Datum:18.10.2013
Board/Management Information Classification · 100% confidence The document is a 'Bericht des Aufsichtsrats' (Report of the Supervisory Board) for Medigene AG for the fiscal year 2007. It details the board's oversight activities, committee work, corporate governance compliance, and the approval of the annual and consolidated financial statements. This type of report is a standard component of a company's annual reporting package, specifically focusing on governance and oversight, which falls under the Governance Information category.
2013-10-18 German
Hinweis auf Quartalsfinanzbericht vom 01.01.2013 bis zum 30.09.2013
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 1,000 characters) that informs shareholders about the availability of a quarterly financial report. It explicitly states 'Hinweis auf Quartalsfinanzbericht' (Notice of Quarterly Financial Report) and provides a link to where the report can be accessed online. Following the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA).
2013-10-17 German
Datum:17.10.2013
Report Publication Announcement Classification · 100% confidence The document is a short notification (900 characters) announcing the availability of a quarterly financial report. It explicitly states 'Hinweis auf Quartalsfinanzbericht' (Notice of Quarterly Financial Report) and provides a link to where the report can be found online. Per the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2013-10-17 German
Datum:10.10.2013
Board/Management Information Classification · 100% confidence The document is the 'Bericht des Aufsichtsrats' (Report of the Supervisory Board) for Medigene AG for the fiscal year 2008. This report is a mandatory component of the German Annual Report (Geschäftsbericht). Since it details the supervisory board's activities, audit oversight, and governance, and is part of the comprehensive annual financial reporting package, it is classified as an Annual Report (10-K).
2013-10-10 German
Datum:01.10.2013
Annual Report Classification · 100% confidence The document is a comprehensive financial report for Medigene AG for the fiscal year 2012. It includes a 'Bestätigungsvermerk' (Audit Opinion), 'Konzern-Bilanz' (Consolidated Balance Sheet), 'Konzern-Gewinn- und Verlustrechnung' (Consolidated Income Statement), 'Konzern-Kapitalflussrechnung' (Cash Flow Statement), 'Konzern-Eigenkapitalveränderungsrechnung' (Statement of Changes in Equity), and a detailed 'Konzern-Anhang' (Notes to the Consolidated Financial Statements). This constitutes a full annual financial report. While the document is in German, the content matches the definition of a 10-K (Annual Report) as it provides the full financial performance and activity for the fiscal year. FY 2012
2013-10-01 German

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.